دورية أكاديمية

[Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].

التفاصيل البيبلوغرافية
العنوان: [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
عنوان ترانسليتريتد: Cardiovasculaire en gastro-intestinale risico's bij selectieve en niet-selectieve NSAID's.
المؤلفون: van den Bemt BJ; Sint Maartenskliniek, afd. Farmacie, Hengstdal 3, 6522 JV Nijmegen. b.vandenbemt@maartenskliniek.nl, Benraad HB, Rasker JJ
المصدر: Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2007 May 12; Vol. 151 (19), pp. 1062-7.
نوع المنشور: English Abstract; Journal Article; Review
اللغة: Dutch; Flemish
بيانات الدورية: Publisher: Vereniging NTvG Country of Publication: Netherlands NLM ID: 0400770 Publication Model: Print Cited Medium: Print ISSN: 0028-2162 (Print) Linking ISSN: 00282162 NLM ISO Abbreviation: Ned Tijdschr Geneeskd Subsets: MEDLINE
أسماء مطبوعة: Publication: 2017?-: Amsterdam : Vereniging NTvG
Original Publication: Houten : Bohn Stafleu van Loghum
مواضيع طبية MeSH: Anti-Inflammatory Agents, Non-Steroidal/*adverse effects , Cardiovascular Diseases/*chemically induced , Cyclooxygenase 2 Inhibitors/*adverse effects , Gastrointestinal Diseases/*chemically induced, Cardiovascular Diseases/epidemiology ; Dyspepsia/chemically induced ; Gastrointestinal Diseases/epidemiology ; Humans ; Risk Factors
مستخلص: There has been much discussion regarding the cardiovascular and gastrointestinal safety of traditional and COX-2 selective NSAIDs. The national and international guidelines differ in their recommendations. Selective COX-2 inhibitors seem to have a diminished risk for severe gastrointestinal complications in the short-term, but the long-term benefit has not yet been proven. In various studies, COX-2 selective NSAIDs have been associated with an increased risk of cardiovascular complications. This connection has been clearly demonstrated only for rofecoxib. Celecoxib seems to lead to an increased risk only at high dosages. However, more patients will have to be followed for a longer period to confirm these results. There is insufficient evidence that the COX-2 selective agents lead to more frequent cardiovascular complications than the traditional NSAIDs. In patients with an increased risk of gastrointestinal complications and no cardiovascular risk, there is no preference for either COX-2 selective NSAIDs or the combination of traditional NSAIDs and a proton pump inhibitor. If dyspepsia develops during the use of a traditional NSAID, then it seems more effective to add a proton-pump inhibitor to the traditional NSAID rather than replacing it by a COX-2 selective NSAID.
Number of References: 53
المشرفين على المادة: 0 (Anti-Inflammatory Agents, Non-Steroidal)
0 (Cyclooxygenase 2 Inhibitors)
تواريخ الأحداث: Date Created: 20070608 Date Completed: 20070626 Latest Revision: 20070607
رمز التحديث: 20240628
PMID: 17552414
قاعدة البيانات: MEDLINE